PortalPublikationenBackground morbidity in HIV vaccine trial participants from ...

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.

Standard

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. / Schmidt, Claudia; Smith, Carol; Barin, Burc; Bakhtyari, Arash; Bart, Pierre-Alexandre; Bekker, Linda-Gail; Chomba, Elwyn; Clumeck, Nathan; Ho, David; Hoosen, Anwar; Jaoko, Walter; Kaleebu, Pontiano; Karita, Etienne; Keefer, Michael C; van Lunzen, Jan; McMichael, Andrew; Mehendale, Sanjay; Peters, Barry; Ramanathan, Vadakkuppatu D; Robinson, Andrew; Rockstroh, Juergen; Vardas, Eftyhia; Vets, Eva; Weber, Jonathan; Graham, Barney S; Than, Soe; Excler, Jean-Louis; Kochhar, Sonali; Ho, Martin; Heald, Alison; Fast, Patricia E.

in: HUM VACC IMMUNOTHER, Jahrgang 8, Nr. 5, 5, 2012, S. 630-638.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schmidt, C, Smith, C, Barin, B, Bakhtyari, A, Bart, P-A, Bekker, L-G, Chomba, E, Clumeck, N, Ho, D, Hoosen, A, Jaoko, W, Kaleebu, P, Karita, E, Keefer, MC, van Lunzen, J, McMichael, A, Mehendale, S, Peters, B, Ramanathan, VD, Robinson, A, Rockstroh, J, Vardas, E, Vets, E, Weber, J, Graham, BS, Than, S, Excler, J-L, Kochhar, S, Ho, M, Heald, A & Fast, PE 2012, 'Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.', HUM VACC IMMUNOTHER, Jg. 8, Nr. 5, 5, S. 630-638. <http://www.ncbi.nlm.nih.gov/pubmed/22634443?dopt=Citation>

APA

Schmidt, C., Smith, C., Barin, B., Bakhtyari, A., Bart, P-A., Bekker, L-G., Chomba, E., Clumeck, N., Ho, D., Hoosen, A., Jaoko, W., Kaleebu, P., Karita, E., Keefer, M. C., van Lunzen, J., McMichael, A., Mehendale, S., Peters, B., Ramanathan, V. D., ... Fast, P. E. (2012). Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. HUM VACC IMMUNOTHER, 8(5), 630-638. [5]. http://www.ncbi.nlm.nih.gov/pubmed/22634443?dopt=Citation

Vancouver

Schmidt C, Smith C, Barin B, Bakhtyari A, Bart P-A, Bekker L-G et al. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. HUM VACC IMMUNOTHER. 2012;8(5):630-638. 5.

Bibtex

@article{ab259008a9a84cf09adbb368b90030b1,
title = "Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.",
abstract = "Recently, more clinical trials are being conducted in Africa and Asia, therefore, background morbidity in the respective populations is of interest. Between 2000 and 2007, the International AIDS Vaccine Initiative sponsored 19 Phase 1 or 2A preventive HIV vaccine trials in the US, Europe, Sub-Saharan Africa and India, enrolling 900 healthy HIV-1 uninfected volunteers.",
keywords = "Adult, Humans, Male, Middle Aged, Adolescent, Young Adult, Double-Blind Method, *Cost of Illness, United States/epidemiology, Europe/epidemiology, Human Experimentation, AIDS Vaccines/*administration & dosage/adverse effects, Africa South of the Sahara/epidemiology, HIV Infections/*prevention & control, India/epidemiology, Placebos/administration & dosage, Adult, Humans, Male, Middle Aged, Adolescent, Young Adult, Double-Blind Method, *Cost of Illness, United States/epidemiology, Europe/epidemiology, Human Experimentation, AIDS Vaccines/*administration & dosage/adverse effects, Africa South of the Sahara/epidemiology, HIV Infections/*prevention & control, India/epidemiology, Placebos/administration & dosage",
author = "Claudia Schmidt and Carol Smith and Burc Barin and Arash Bakhtyari and Pierre-Alexandre Bart and Linda-Gail Bekker and Elwyn Chomba and Nathan Clumeck and David Ho and Anwar Hoosen and Walter Jaoko and Pontiano Kaleebu and Etienne Karita and Keefer, {Michael C} and {van Lunzen}, Jan and Andrew McMichael and Sanjay Mehendale and Barry Peters and Ramanathan, {Vadakkuppatu D} and Andrew Robinson and Juergen Rockstroh and Eftyhia Vardas and Eva Vets and Jonathan Weber and Graham, {Barney S} and Soe Than and Jean-Louis Excler and Sonali Kochhar and Martin Ho and Alison Heald and Fast, {Patricia E}",
year = "2012",
language = "English",
volume = "8",
pages = "630--638",
journal = "HUM VACC IMMUNOTHER",
issn = "2164-5515",
publisher = "LANDES BIOSCIENCE",
number = "5",

}

RIS

TY - JOUR

T1 - Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.

AU - Schmidt, Claudia

AU - Smith, Carol

AU - Barin, Burc

AU - Bakhtyari, Arash

AU - Bart, Pierre-Alexandre

AU - Bekker, Linda-Gail

AU - Chomba, Elwyn

AU - Clumeck, Nathan

AU - Ho, David

AU - Hoosen, Anwar

AU - Jaoko, Walter

AU - Kaleebu, Pontiano

AU - Karita, Etienne

AU - Keefer, Michael C

AU - van Lunzen, Jan

AU - McMichael, Andrew

AU - Mehendale, Sanjay

AU - Peters, Barry

AU - Ramanathan, Vadakkuppatu D

AU - Robinson, Andrew

AU - Rockstroh, Juergen

AU - Vardas, Eftyhia

AU - Vets, Eva

AU - Weber, Jonathan

AU - Graham, Barney S

AU - Than, Soe

AU - Excler, Jean-Louis

AU - Kochhar, Sonali

AU - Ho, Martin

AU - Heald, Alison

AU - Fast, Patricia E

PY - 2012

Y1 - 2012

N2 - Recently, more clinical trials are being conducted in Africa and Asia, therefore, background morbidity in the respective populations is of interest. Between 2000 and 2007, the International AIDS Vaccine Initiative sponsored 19 Phase 1 or 2A preventive HIV vaccine trials in the US, Europe, Sub-Saharan Africa and India, enrolling 900 healthy HIV-1 uninfected volunteers.

AB - Recently, more clinical trials are being conducted in Africa and Asia, therefore, background morbidity in the respective populations is of interest. Between 2000 and 2007, the International AIDS Vaccine Initiative sponsored 19 Phase 1 or 2A preventive HIV vaccine trials in the US, Europe, Sub-Saharan Africa and India, enrolling 900 healthy HIV-1 uninfected volunteers.

KW - Adult

KW - Humans

KW - Male

KW - Middle Aged

KW - Adolescent

KW - Young Adult

KW - Double-Blind Method

KW - Cost of Illness

KW - United States/epidemiology

KW - Europe/epidemiology

KW - Human Experimentation

KW - AIDS Vaccines/administration & dosage/adverse effects

KW - Africa South of the Sahara/epidemiology

KW - HIV Infections/prevention & control

KW - India/epidemiology

KW - Placebos/administration & dosage

KW - Adult

KW - Humans

KW - Male

KW - Middle Aged

KW - Adolescent

KW - Young Adult

KW - Double-Blind Method

KW - Cost of Illness

KW - United States/epidemiology

KW - Europe/epidemiology

KW - Human Experimentation

KW - AIDS Vaccines/administration & dosage/adverse effects

KW - Africa South of the Sahara/epidemiology

KW - HIV Infections/prevention & control

KW - India/epidemiology

KW - Placebos/administration & dosage

M3 - SCORING: Journal article

VL - 8

SP - 630

EP - 638

JO - HUM VACC IMMUNOTHER

JF - HUM VACC IMMUNOTHER

SN - 2164-5515

IS - 5

M1 - 5

ER -